<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2014-06-17" updated="2019-12-02">
  <drugbank-id primary="true">DB09005</drugbank-id>
  <name>Batroxobin</name>
  <description>Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids.&#13;
&#13;
Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds.  Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity. Once bound to fibrin, it will cause fibrin accretion(clot formation) to a degree 18 folds greater than thrombin. &#13;
&#13;
Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production.</description>
  <cas-number>9039-61-6</cas-number>
  <unii>47RYF40GA9</unii>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A14447</ref-id>
        <pubmed-id>6672998</pubmed-id>
        <citation>Mannucci PM, Mari D: [Fibrinolytic and defibrinogenation therapy]. Ric Clin Lab. 1983;13 Suppl 3:245-55.</citation>
      </article>
      <article>
        <ref-id>A14448</ref-id>
        <pubmed-id>23612970</pubmed-id>
        <citation>Vu TT, Stafford AR, Leslie BA, Kim PY, Fredenburgh JC, Weitz JI: Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. J Biol Chem. 2013 Jun 7;288(23):16862-71. doi: 10.1074/jbc.M113.464750. Epub 2013 Apr 23.</citation>
      </article>
      <article>
        <ref-id>A14449</ref-id>
        <pubmed-id>21570870</pubmed-id>
        <citation>Wang J, Zhu YQ, Li MH, Zhao JG, Tan HQ, Wang JB, Liu F, Cheng YS: Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. J Vasc Interv Radiol. 2011 Jul;22(7):987-94. doi: 10.1016/j.jvir.2011.03.015. Epub 2011 May 14.</citation>
      </article>
      <article>
        <ref-id>A14450</ref-id>
        <pubmed-id>17287638</pubmed-id>
        <citation>Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X: Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis. 2007 Mar;18(2):193-7.</citation>
      </article>
      <article>
        <ref-id>A14451</ref-id>
        <pubmed-id>24487019</pubmed-id>
        <citation>You KE, Koo MA, Lee DH, Kwon BJ, Lee MH, Hyon SH, Seomun Y, Kim JT, Park JC: The effective control of a bleeding injury using a medical adhesive containing batroxobin. Biomed Mater. 2014 Apr;9(2):025002. doi: 10.1088/1748-6041/9/2/025002. Epub 2014  Jan 31.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.</indication>
  <pharmacodynamics>Insensitive to thrombin inhibitors and capable of clotting platelet rich plasma without affecting platelet function.&#13;
</pharmacodynamics>
  <mechanism-of-action>Batroxobin is a thrombin like serine protease enzyme that will cleave fibrinogen. Cleavage at the16 Arginine - 17 Glycine bond in the A alpha chain of fibrinogen releases fibrinopeptide A and forms a fibrin I monomer that will spontaneously aggregate into a clot. The reduction of plasma fibrinogen by formation of fibrin microclots that are easily cleared by the reticuloendothelial system &#13;
can decrease high blood viscosity which contributes to the formation of thromboemboli.&#13;
&#13;
In addition, batroxobin is reported to induce fibrinolysis by inducing the endothelial release of tissue plasminogen activator (tPA) from vascular endothelial cells. This effect may potentially be dose dependant.&#13;
&#13;
 &#13;
&#13;
</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/jan">Batroxobin</synonym>
    <synonym language="spanish" coder="inn">Batroxobina</synonym>
    <synonym language="french" coder="inn">Batroxobine</synonym>
    <synonym language="latin" coder="inn">Batroxobinum</synonym>
    <synonym language="english" coder="">Bothrops atrox blood-coagulation factor X activator</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Ba Qu Ting</name>
      <company>Belda Gaoke Huatal Pharmaceutical, China</company>
    </international-brand>
    <international-brand>
      <name>Batraxobin</name>
      <company>Tobishi Pharmaceutical, China</company>
    </international-brand>
    <international-brand>
      <name>Botroclot</name>
      <company>Juggat, India</company>
    </international-brand>
    <international-brand>
      <name>Botropase</name>
      <company>Han Lim, South Korea</company>
    </international-brand>
    <international-brand>
      <name>Defibrase</name>
      <company>Tobishi Pharmaceutical, Japan</company>
    </international-brand>
    <international-brand>
      <name>Reptilase</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Su Le Juan</name>
      <company>Zhaoke Pharmaceutical, China</company>
    </international-brand>
    <international-brand>
      <name>Su Ling</name>
      <company>Kangchen Pharmaceutical, China</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bodily Secretions</category>
      <mesh-id>D012634</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Coagulants</category>
      <mesh-id>D003029</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Crotalid Venoms</category>
      <mesh-id>D003435</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Fluids and Secretions</category>
      <mesh-id>D005441</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
    <category>
      <category>Snake Venoms</category>
      <mesh-id>D012910</mesh-id>
    </category>
    <category>
      <category>Toxins, Biological</category>
      <mesh-id>D014118</mesh-id>
    </category>
    <category>
      <category>Venombin A</category>
      <mesh-id>D020791</mesh-id>
    </category>
    <category>
      <category>Venoms</category>
      <mesh-id>D014688</mesh-id>
    </category>
    <category>
      <category>Viper Venoms</category>
      <mesh-id>D014757</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes>
    <atc-code code="B02BX03">
      <level code="B02BX">Other systemic hemostatics</level>
      <level code="B02B">VITAMIN K AND OTHER HEMOSTATICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Batroxobin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>